KoiHaus, a mid-century modern home on three-and-a-quarter acres near Piermont, New York, rises from a secluded road near the ...

Back in March, President Donald Trump claimed that an expensive renovation to a White House pathway was paid for by himself personally, but on Friday, The Atlantic’s Michael Scherer revealed that the ...

Instead, Trump wanted polished African granite, carved in Italy, with a flamed-finish stripe—slightly raised, to prevent slips—running down the middle. As workers tore up the flagstone in March, a ...

Tucked into a tiny pocket of native trees, shrubs and plantings on one of Melbourne’s busiest corners is a surprising monument. Its colourful, varied shapes and forms suggest a playful contemporary ...

In a time when the workforce is evolving faster than ever, Michelle Blue is focused on one central mission: ensuring young people are not left behind. As the founder of Next YE Development, Blue has ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Lizzy leads STAT’s coverage of the FDA. Her ...

After teasing a new regulatory process for personalized genetic medicines at the end of last year, the FDA today unveiled draft guidance for an approval pathway that could see custom CRISPR therapies, ...

Compass Pathways has announced that its investigational psilocybin treatment has successfully met its primary endpoint in a second Phase 3 clinical trial moving it one step closer to FDA submission.

NEW YORK, Nov 12 (Reuters) - The U.S. Food and Drug Administration can approve new personalized treatments for rare and deadly genetic diseases based on data from a handful of patients, two of the ...

In a highly anticipated article, FDA officials Vinay Prasad, M.D., and Martin Makary, M.D., outlined a novel regulatory pathway that could trigger a seismic shift in how bespoke gene editing therapies ...